Generic drugmaker Sandoz’s shares fall after sales outlook lowered

ZURICH, Oct 28 (Reuters) - Swiss generic drugmaker Sandoz on Wednesday lowered its full-year sales growth guidance and lifted its core earnings margin forecasts after short-term biosimilar-supply constraints weighed on third-quarter results, sending shares down over 5% in early trading. The company now expects net sales to grow by 5-6% at constant exchange rates, from mid-to-high-single-digit…